Search 

GCA Therapeutics Ltd (GCAT) is a US based, specialty pharmaceutical company focusing on in-licensing, acquisition and marketing of mid through late stage drug candidates and technologies from North America and the EU. GCAT applies its expertise and resources in pre-clinical, clinical, and final regulatory review and approval phases to commercialize products for use in the Chinese market. GCAT is currently in discussion with several US and European biotech and pharma firms to bring several important drugs to market through its joint venture in Tianjin, China. Initially, GCAT will market its products through a 3rd party distribution/sales partnership and will construct or acquire manufacture capabilities in China at a later date. GCAT currently has operations in New Jersey, New York, Shanghai, and Beijing.

GeneDx specializes in genetic testing for rare hereditary disorders. Our mission is to make clinical testing available to people with rare genetic conditions and their families. Most of our tests include full gene analysis by DNA sequencing, the gold standard of genetic testing. We invite you to explore our site, where you will find comprehensive information and all of our paperwork. Please note that GeneDx does not provide Direct-to-Consumer testing. All tests must be ordered, and results sent to a health care provider, usually a physician or genetic counselor. Families are encouraged to present our material to their health care providers who can evaluate the appropriateness of testing. For diagnostic testing in rare disorders, contact GeneDx… Where rare is common.

GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory and clinical services. 

From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. 

At GENEWIZ, it is our mission to contribute to the advancement of life sciences and technologies. Together with our clients, we can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Our goal is to be the best in the world and the best for the world. 

Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

DNA Sequencing; Gene Synthesis; Mutation Analysis; SNP Discovery; Sequencing from Bacteria and Phage; Difficult Template Sequencing; Plasmid Preparation; Site-directed Mutagenesis; Fragment Analysis

From helping Tenet Healthcare stave off a hostile takeover to obtaining summary judgment for a former health care general counsel in a precedent-setting False Claims Act case to establishing ERISA preemption precedent in the United States Supreme Court on behalf of Aetna, achieving successful outcomes for our clients in their most important matters is our singular focus.

GLG Pharma has been selected for the National Cancer Institute's Prevent Cancer development program. Click here for the most recent news. 

Cancer is a very complicated disease and no two cell cancers are similar but some generalizations of how this terrible disease progresses has been extensively studied and researched. This simple cartoon is meant to show just one pathway used by cancer cells to exploit the body's natural defensive mechanisms and reach a state of perptual immortality, allowing the cancer cells to grow, regardless of the consequences to the overall health of the host patient.

GLOBAL CARE Initiative is a French consortium of five non-profit Carnot research institutes dedicated to human health.

• CALYM, the Consortium for the acceleration of innovation and its transfer to the field of Lymphoma
• Curie Cancer, a component of Institut Curie focused on cancers
• ICM, the Brain and Spine Institute dedicated to CNS diseases
• Pasteur MI, the infectious diseases division of the Institut Pasteur
• Voir et Entendre, expert in vision and audition diseases and rehabilitation

Our goal is to operate as a one-stop shop to life sciences companies and research and technological organizations that seek effective R&D partnerships. The Carnot Institutes can collaborate at any stage — from basic research to late clinical phases. GLOBAL CARE Initiative combines strong scientific expertise to unique technology platforms to propose an innovation-centered collaboration offer.

CNS Diseases, Vision and Audition Diseases, Cancers, Lymphoma, Infectious Diseases

The institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other RTOs.

The consortium operates as a one-stop-shop for life science companies and research organizations that seek R&D collaboration from basic research to the late clinical phases

Basic research / Preclinical research / Clinical

One stop shop for all of the insitutes / Translational research collaborations (biobanks-clinical data/trials - Epidemiologic data - Animal/cells models) / Access to European market (Patient population/Cormecial market/ European KOLs/clinical centers)/New sourcing for innovation

Global research and consulting for the energy and healthcare industries

GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

Combining precision with innovation, our research and consulting solutions ensure our clients stay at the forefront of their markets by integrating accurate market forecasts and analysis on the latest trends and developments with the unrivalled expertise of our analyst teams. Among other benefits, our informed industry perspectives help clients understand how to generate the maximum return from their key markets, identify opportunities from emerging trends, and devise strategies for growth with confidence.

1) Developement of patented injectable resorbable biomaterials which harden in situ, allowing minimally invasive surgery and are quickly resorbed by the cellular activity and replaced by natural bone. 2) Design and development of combinaison devices utilizing synthetic bone substitute materials and therapeutic agents as well as autologous tissue which will address such clinical challenges as prevention of osteoporotic fractures, prevention of infection and enhanced bone ingrowth

1) Bone defect filling via MIS techniques for younger patients; 2) "Super-Fast" resorption and remodeling to boost bone reconstruction for non union management; 3) Local treatment or prevention of osteoporotic patient ; 4) management of bone Infection by our innovative calcium phosphate cement combined with antibiotic (exposed trauma, military application...)

1) Orthopaedic: Trauma and Reconstruction; 2) Spine Surgery; 3)Dentistry

1) Patented technology which provides unique soluctions to address key clinical needs; 2) Proprietary pipeline of innovative bone tissue engineering solutions; 3) Fully integrated organization and facilities which include R&D, manufacturing, regulatory, sales and marketing; 4) Strong relationships with leading global orthopedic companies; 5) years of very successful sales and clinical experience in 23 countries of the world